ClinicalTrials.gg

Carcinoma, Non-Small-Cell Lung clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 7,632 studies for Carcinoma, Non-Small-Cell Lung across more than 10 countries. 1,839 are recruiting or about to start. 6,217 of them are mainly about Carcinoma, Non-Small-Cell Lung (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 8,610 studies for Carcinoma, Non-Small-Cell Lung. How that becomes 7,624 hereChecked on ClinicalTrials.gov Nov 15, 2026

This page counts the studies the registry files under Carcinoma, Non-Small-Cell Lung, and those it files under no condition that list Carcinoma, Non-Small-Cell Lungthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Its counts are asked again about once a week. How condition pages count

  1. 8,610Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −146List Carcinoma, Non-Small-Cell Lung as a condition, but the registry did not file them under itMost often written as “Non-small Cell Lung Cancer Metastatic” (12), “EGFR Positive Non-small Cell Lung Cancer” (9), and “Advanced Non-small Cell Lung Cancer” (8). The registry filed them under other conditions only, most often Lung Neoplasms (38) and Neoplasm Metastasis (18).
  3. −843Match it another way745 name it in the title, 18 in a keyword, and 80 by a synonym or other text the search reads.
  4. 7,621Counted here and found by its search519 of them list Carcinoma, Non-Small-Cell Lung in their own words; the registry filed them under no condition.
  5. +3
    Counted here, but its search does not find them
  6. 7,624The count on this page

Status

Completed
2,952
Recruiting
1,324
Terminated
986
Status unknown
876
Active, not recruiting
656
Not yet recruiting
469

Phase

Phase 2
3,402
Phase 1
2,077
Phase 3
918
Phase 4
105
Early Phase 1
63

Where

United States
3,371
China
1,881
France
874
Spain
851
Italy
715
Korea, Republic of
701

Who develops what

Add Carcinoma, Non-Small-Cell Lung to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 317 programs from 172 companies, 238 with this as their studies’ main aim; 87 with a live phase 3 study; 75 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Bristol-Myers Squibb and Pfizer here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07890714 · Daiichi Sankyo · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2026
  • NCT07865910 · Fosun Pharma · Phase 3 · live · comparator · “PEMBROLIZUMAB (alone or when added to a regimen above)” · registered Oct 2026
  • NCT07845786 · Exelixis · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2026
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pembrolizumab” · registered Aug 2026
  • NCT07756645 · AbbVie · Phase 3 · live · comparator · “Pembrolizumab” · registered Aug 2026
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)5686 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “cisplatin or carboplatin” · registered Oct 2026
  • NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Carboplatin injection” · registered Oct 2026
  • NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Oct 2026
  • NCT07865910 · Fosun Pharma · Phase 3 · live · background · “Carboplatin (Investigator discretion)” · registered Oct 2026
  • NCT07845786 · Exelixis · Phase 2 · live · background · “Carboplatin” · registered Sep 2026
Eli Lilly and Company16% of its industry studies53109 studies
PemetrexedRecent, repeated
Evidence
  • NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “pemetrexed” · registered Oct 2026
  • NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pemetrexed Disodium For Injection” · registered Oct 2026
  • NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Oct 2026
  • NCT07865910 · Fosun Pharma · Phase 3 · live · background · “Pemetrexed (1)” · registered Oct 2026
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized4791 studies
DocetaxelRecent, repeated
Evidence
  • NCT07821684 · AbbVie · Phase 3 · live · comparator · “Docetaxel” · registered Sep 2026
  • NCT07668752 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
  • NCT07660094 · Candel Therapeutics, Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
  • NCT07609251 · Sinocelltech Group Limited · Phase 2 · live · background · “docetaxel” · registered May 2026
  • NCT07566052 · Astellas Pharma Inc · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized3438 studies
CisplatinRecent, repeated
Evidence
  • NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “cisplatin or carboplatin” · registered Oct 2026
  • NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Cisplatin injection” · registered Oct 2026
  • NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Oct 2026
  • NCT07822542 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · background · “Cisplatin” · registered Sep 2026
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed3065 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Oct 2026
  • NCT07845786 · Exelixis · Phase 2 · live · background · “Paclitaxel” · registered Sep 2026
  • NCT07756645 · AbbVie · Phase 3 · live · background · “Paclitaxel” · registered Aug 2026
  • NCT07739199 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
  • NCT07680764 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Jun 2026
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed2342 studies
osimertinibRecent, repeated
Evidence
  • NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “osimertinib” · registered Oct 2026
  • NCT07680790 · Bristol-Myers Squibb · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
  • NCT07669779 · Akeso · Phase 2 · live · background · “Osimertinib” · registered Jun 2026
  • NCT07642024 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
  • NCT07640789 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016)1627 studies
tislelizumabRecent, repeated
Evidence
  • NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab Injection” · registered Oct 2026
  • NCT07846358 · Genfleet Therapeutics (Shanghai) Inc. · Phase 2 · live · background · “with or without Tislelizumab” · registered Sep 2026
  • NCT07822542 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Tislelizumab” · registered Sep 2026
  • NCT07739186 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab” · registered Jul 2026
  • NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Tislelizumab” · registered Jun 2026
BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023)1516 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07845786 · Exelixis · Phase 2 · live · background · “Nab-paclitaxel” · registered Sep 2026
  • NCT07756645 · AbbVie · Phase 3 · live · background · “Nab- Paclitaxel” · registered Aug 2026
  • NCT07662395 · Sinocelltech Group Limited · Phase 3 · live · background · “Nab-paclitaxel” · registered Jun 2026
  • NCT07365319 · Eikon Therapeutics · Phase 3 · live · background · “Nab-paclitaxel + Carboplatin” · registered Jan 2026
  • NCT07221474 · Merck & Co., Inc · Phase 2 · live · background · “Nab-paclitaxel” · registered Oct 2025
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)1117 studies
NivolumabRecent, repeated
Evidence
  • NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
  • NCT07541170 · Hoffmann-La Roche · Phase 3 · live · comparator · “Nivolumab” · registered Apr 2026
  • NCT07246863 · CatalYm GmbH · Phase 2 · live · background · “Nivolumab” · registered Nov 2025
  • NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Nivolumab” · registered Sep 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)99 studies
GemcitabineRecent, repeated
Evidence
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT07005336 · TJ Biopharma Co., Ltd. · Phase 2 · live · background · “Gemcitabine” · registered May 2025
  • NCT06908304 · Maia Biotechnology · Phase 3 · live · comparator · “Gemcitabine alone” · registered Mar 2025
  • NCT06623422 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Sep 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed67 studies
BevacizumabRecent, repeated
Evidence
  • NCT06730750 · Bristol-Myers Squibb · Phase 2 · live · background · “Bevacizumab” · registered Dec 2024
  • NCT06512051 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab Injection” · registered Jul 2024
  • NCT06303505 · Gilead Sciences · Phase 2 · live · background · “Bevacizumab” · registered Feb 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others67 studies
durvalumabRecent, repeated
Evidence
  • NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Durvalumab” · registered Jun 2026
  • NCT07554339 · Merck & Co., Inc · Phase 3 · live · background · “Durvalumab” · registered Apr 2026
  • NCT07361497 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Durvalumab” · registered Jan 2026
  • NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Durvalumab” · registered Sep 2025
  • NCT06667908 · Johnson & Johnson · Phase 2 · live · background · “Durvalumab” · registered Oct 2024
AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018)67 studies
CetuximabRecent, repeated
Evidence
  • NCT07939815 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Nov 2026
  • NCT07468071 · Novartis · Phase 2 · live · background · “cetuximab” · registered Mar 2026
  • NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “cetuximab (Cohort C2 Only)” · registered Feb 2026
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004)69 studies
CrizotinibRecent, repeated
Evidence
  • NCT07816380 · Guangzhou JOYO Pharma Co., Ltd · Phase 3 · live · comparator · “Crizotinib Capsules” · registered Sep 2026
  • NCT06564324 · Nuvation Bio Inc. · Phase 3 · live · comparator · “Crizotinib” · registered Aug 2024
  • NCT06140836 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Crizotinib” · registered Nov 2023
  • NCT06082635 · Shenzhen TargetRx, Inc. · Phase 3 · live · comparator · “Crizotinib” · registered Oct 2023
  • NCT05204628 · Sihuan Pharmaceutical Holdings Group Ltd. · Phase 3 · live · comparator · “Crizotinib” · registered Dec 2021
Pfizer94% of its industry studiesUS: Pfizer (FDA 2011)EU: Pfizer (EMA 2012)55 studies
cemiplimabRecent, repeated
Evidence
  • NCT06090266 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2023
  • NCT05317858 · insightec · Phase 3 · live · background · “Cemiplimab” · registered Mar 2022
  • NCT05259696 · Palleon Pharmaceuticals, Inc. · Phase 2 · background · “Cemiplimab” · registered Feb 2022
  • NCT05208944 · Maia Biotechnology · Phase 2 · live · background · “Cemiplimab” · registered Dec 2021
  • NCT05094804 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2021
Regeneron Pharmaceuticals83% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2018)EU: Regeneron Pharmaceuticals (EMA 2019)44 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07874984 · 3SBio Inc. · Phase 2 · live · background · “Chemotherapy” · registered Sep 2026
  • NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jan 2024
  • NCT05787613 · Fosun Pharma · Phase 2 · live · background · “Chemotherapy drug” · registered Mar 2023
  • NCT05098990 · China Resources Pharmaceutical Group Limited · Phase 4 · comparator · “Platinum-based doublet chemotherapy” · registered Sep 2021
  • NCT04951648 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · comparator · “chemotherapy” · registered Jun 2021
—33 studies
VinorelbineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06908304 · Maia Biotechnology · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2025
  • NCT06564844 · AstraZeneca · Phase 3 · live · comparator · “Vinorelbine” · registered Aug 2024
  • NCT05487391 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Vinorelbine Tartrate” · registered Aug 2022
  • NCT03770299 · Bristol-Myers Squibb · Phase 2 · background · “Vinorelbine” · registered Dec 2018
  • NCT03456076 · Hoffmann-La Roche · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2018
Eli Lilly and Company9% of its industry studies33 studies
ivonescimabRecent, repeated
Evidence
  • NCT07603791 · Shanghai Allink Biotherapeutics Co., Ltd. · Phase 2 · live · background · “Ivonescimab Injection” · registered May 2026
  • NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Ivonescimab” · registered Feb 2026
  • NCT07208773 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2 · live · background · “Ivonescimab” · registered Sep 2025
Akeso81% of its industry studies33 studies
toripalimabRecent, repeated
Evidence
  • NCT06623136 · Elpiscience (Suzhou) Biopharma, Ltd. · Phase 2 · live · background · “Toripalimab” · registered Sep 2024
  • NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
  • NCT05386888 · Genfleet Therapeutics (Shanghai) Inc. · Phase 2 · background · “Toripalimab” · registered May 2022
RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024)33 studies
DexamethasoneRecent, repeated
Evidence
  • NCT06305754 · Merck & Co., Inc · Phase 3 · live · background · “Dexamethasone (or equivalent)” · registered Mar 2024
  • NCT05663866 · Johnson & Johnson · Phase 2 · live · background · “Dexamethasone” · registered Dec 2022
  • NCT05070247 · Takeda · Phase 2 · background · “Dexamethasone” · registered Sep 2021
  • NCT04786964 · Sun Pharmaceutical Industries Limited · Phase 3 · background · “Dexamethasone 4mg” · registered Mar 2021
  • NCT04300556 · Eisai Co., Ltd. · Phase 2 · live · background · “Dexamethasone” · registered Mar 2020
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)22 studies
IpilimumabRecent, repeated
Evidence
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
  • NCT04665206 · Vivace Therapeutics, Inc · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Dec 2020
  • NCT03989362 · Jounce Therapeutics, Inc. · Phase 2 · background · “Ipilimumab” · registered Jun 2019
  • NCT03739710 · GlaxoSmithKline · Phase 2 · background · “Ipilimumab” · registered Nov 2018
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies
atezolizumabRecent, repeated
Evidence
  • NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Atezolizumab” · registered Sep 2025
  • NCT05317858 · insightec · Phase 3 · live · background · “Atezolizumab” · registered Mar 2022
  • NCT04984811 · NeoImmuneTech · Phase 2 · background · “Atezolizumab” · registered Jul 2021
  • NCT04471415 · Dracen Pharmaceuticals, Inc. · Phase 2 · background · “atezolizumab” · registered Jun 2020
  • NCT04440735 · Kahr Medical · Phase 2 · live · background · “Atezolizumab” · registered Jun 2020
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies
CapecitabineRecent, repeated
Evidence
  • NCT06253871 · Iambic Therapeutics, Inc · Phase 2 · live · background · “Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab” · registered Feb 2024
  • NCT05785741 · DualityBio Inc. · Phase 2 · live · background · “capecitabine” · registered Mar 2023
  • NCT05091528 · Silverback Therapeutics · Phase 2 · background · “capecitabine” · registered Oct 2021
  • NCT03169738 · ImmunityBio, Inc. · Phase 2 · background · “Capecitabine” · registered May 2017
  • NCT00732810 · Merck & Co., Inc · Phase 2 · comparator · “Capecitabine” · registered Aug 2008
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized22 studies
EtoposideRecent, repeated
Evidence
  • NCT06564844 · AstraZeneca · Phase 3 · live · comparator · “Etoposide” · registered Aug 2024
  • NCT05298423 · Merck & Co., Inc · Phase 3 · background · “etoposide” · registered Mar 2022
  • NCT04380636 · Merck & Co., Inc · Phase 3 · live · background · “Etoposide” · registered May 2020
  • NCT04203511 · Incyte Corporation · Phase 3 · background · “Etoposide” · registered Dec 2019
  • NCT03840902 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Etoposide” · registered Feb 2019
Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed22 studies
enzalutamideRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
  • NCT04557449 · Pfizer · Phase 2 · live · background · “Enzalutamide” · registered Sep 2020
  • NCT03568656 · CellCentric Ltd. · Phase 2 · background · “Enzalutamide” · registered Jun 2018
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized22 studies
trametinibRecent, repeated
Evidence
  • NCT07468071 · Novartis · Phase 2 · live · background · “trametinib” · registered Mar 2026
  • NCT05358249 · Novartis · Phase 2 · background · “trametinib” · registered Apr 2022
  • NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
  • NCT02580708 · Clovis Oncology, Inc. · Phase 2 · background · “Trametinib” · registered Oct 2015
  • NCT01336634 · Novartis · Phase 2 · background · “Trametinib” · registered Apr 2011
GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014)23 studies
RamucirumabRecent, repeated
Evidence
  • NCT07821684 · AbbVie · Phase 3 · live · comparator · “Ramucirumab” · registered Sep 2026
  • NCT07098338 · AstraZeneca · Phase 2 · live · background · “Ramucirumab” · registered Jul 2025
  • NCT06448754 · AstraZeneca · Phase 2 · live · background · “Ramucirumab” · registered Jun 2024
  • NCT04394624 · Sanofi · Phase 2 · background · “ramucirumab” · registered May 2020
Eli Lilly and Company91% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014)23 studies
sotorasibRecent, repeated
Evidence
  • NCT07563738 · Orion Corporation, Orion Pharma · Phase 2 · live · background · “sotorasib” · registered Apr 2026
  • NCT06497556 · Hoffmann-La Roche · Phase 3 · live · comparator · “Sotorasib” · registered Jul 2024
Amgen86% of its industry studiesUS: Amgen (FDA 2021)EU: Amgen (EMA 2022)22 studies
aflutinibRecent, repeated
Evidence
  • NCT07622186 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Furmonertinib” · registered May 2026
  • NCT06962865 · RemeGen Co., Ltd. · Phase 2 · live · background · “Furmonertinib Mesilate Tablets Monotherapy” · registered Apr 2025
Allist Pharmaceuticals, Inc.52% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Sep 2022
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
  • NCT03574649 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2018
  • NCT03169738 · ImmunityBio, Inc. · Phase 2 · background · “cyclophosphamide” · registered May 2017
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
  • NCT03568656 · CellCentric Ltd. · Phase 2 · background · “Abiraterone acetate” · registered Jun 2018
  • NCT02711137 · Incyte Corporation · Phase 2 · background · “Abiraterone” · registered Mar 2016
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized22 studies
aldesleukinRecent, repeated
Evidence
  • NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Aldesleukin” · registered Sep 2022
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Aldesleukin” · registered Feb 2022
Chiron Corporation45% of its industry studiesUS: Chiron Corporation (FDA 1992)22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Fludarabine” · registered Sep 2022
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies

73 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
sacituzumab tirumotecan☆ Track4 live phase-3 studies: NCT06670196, NCT06711900, NCT06448312Sichuan Kelun Pharmaceutical Co.,Ltd.
izalontamab brengitecan☆ Track7 live phase-3 studies: NCT06838273, NCT07739199, NCT07739186Sichuan Biokin Pharmaceutical Co., Ltd.
ruzaltatug rezetecan☆ Track3 live phase-3 studies: NCT07895992, NCT07183189, NCT06671379Jiangsu HengRui Medicine Co., Ltd.
QL2107☆ Track1 live phase-3 study: NCT07162883Qilu Pharmaceutical Co., Ltd.
datopotamab deruxtecanApproved: US 2025 · EU 2025☆ Track6 live phase-3 studies: NCT07291037, NCT06357533, NCT06417814AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 317 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (75)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.sacituzumab tirumotecan · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 main aimadded to pembrolizumabNCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — primary endpoint: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) · 406 enrolled
  • Nov 2026 est.andamertinib · Avistone Biotechnology Co., Ltd. · Phase 2 main aimNCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations — primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). · 40 enrolled
  • 30 Nov 2026 est.Anti-EGFR Antibody-drug Conjugate CPO301 · CSPC Pharmaceutical Group Limited · Phase 2 main aim+ Osimertinib vs Carboplatin+ Osimertinib vs Pemetrexed+ Osimertinib vs CisplatinNCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer — primary endpoint: Major Pathological Response (MPR) Rate · 120 enrolled

72 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Non-Small-Cell Lung studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 257 open · Tyrosine kinase inhibitors (TKIs) 202 open · Antibody-drug conjugates (ADCs) 40 open · Antimetabolites 28 open · Antimitotic agents 26 open

Coming up

659studies finish main data collection within a year59 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger. 34 (3%) take children under 18. 1 (<1%) are for women only and 2 (<1%) for men only; 40 (3%) take healthy volunteers.

Recruiting studies that take each age, of 1,324
AgeWomenMen
1028 (2%)28 (2%)
181,267 (96%)1,267 (96%)
301,300 (98%)1,300 (98%)
401,303 (98%)1,303 (98%)
501,305 (99%)1,305 (99%)
651,316 (99%)1,317 (99%)
751,284 (97%)1,285 (97%)
851,053 (80%)1,053 (80%)

Across all 7,632 studies, recruiting or not: 14% stop at 75 or younger and 1% at 65; 4% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Non-Small-Cell Lung studies take

Of 1,046 phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo31–70 · 700 studies49 mo29–66 · 474 studies54 mo36–80 · 226 studies
Phase 1/262 mo41–80 · 434 studies58 mo39–77 · 311 studies69 mo46–107 · 123 studies
Phase 248 mo30–76 · 1,046 studies37 mo24–59 · 317 studies56 mo36–84 · 729 studies
Phase 2/353 mo40–… · 56 studies——
Phase 345 mo30–69 · 424 studies39 mo27–57 · 315 studies81 mo49–129 · 109 studies
Phase 435 mo22–48 · 43 studies——
Interventional, no phase51 mo26–97 · 360 studies—52 mo28–98 · 344 studies
Observational55 mo35–83 · 500 studies49 mo31–64 · 142 studies58 mo36–126 · 358 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting28

Show 23 more

Newly registered59

Show 45 more

and 9 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 7,632. Browse all 7,632 → or search them.